Jan Stenvang

Jan Stenvang

Associate Professor

ORCID: 0000-0001-5647-4828

Publication year:
All
81 - 84 out of 84Page size: 10
Sort by: Title
  1. Published

    A phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2- negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene: a study protocol

    Kümler, Iben, Balslev, E., Stenvang, Jan, Brünner, N. & Nielsen, D., 2015, In: B M C Cancer. 15, 5 p., 78.

    Research output: Contribution to journal › Journal article › Research › peer-review

  2. Published

    A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification

    Tarpgaard, L. S., Qvortrup, C., Nygård, S. B., Nielsen, Signe Lykke, Andersen, D. R., Jensen, N. F., Stenvang, Jan, Detlefsen, S., Brünner, N. & Pfeiffer, P., 2016, In: B M C Cancer. 16, 5 p., 91.

    Research output: Contribution to journal › Journal article › Research › peer-review

  3. Published

    A novel dual-target steroid sulfatase inhibitor and antiestrogen: SR 16157, a promising agent for the therapy of breast cancer

    Rasmussen, L. M., Zaveri, N. T., Stenvang, Jan, Peters, R. H. & Lykkesfeldt, A. E., 2007, In: Breast Cancer Research and Treatment. 106, 2, p. 191-203 12 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  4. Published

    A Comprehensive RNA Study to Identify circRNA and miRNA Biomarkers for Docetaxel Resistance in Breast Cancer

    Huang, P., Li, F., Mo, Z., Geng, C., Wen, F., Zhang, C., Guo, J., Wu, S., Li, L., Brunner, N. & Stenvang, Jan, 2021, In: Frontiers in Oncology. 11, 14 p., 669270.

    Research output: Contribution to journal › Journal article › Research › peer-review

Previous 1...5 6 7 8 9 Next

ID: 12922